Allergy Therapeutics risk profile
79 Stretched several inputs deteriorating together
Measured 21 October 2026 from AGY's filed statements. Recomputed nightly.
79 (Stretched), driven by Cash conversion at 100, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 82 | Acute | Stable | Drawdown from the 52-week high — 62.8% |
| Operating pressure | 43 | Elevated | Worsening | Operating-margin drift — -34.3 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.12x |
| Leverage and coverage | 92 | Acute | Worsening | Net debt to EBITDA |
| Competitive position | 89 | Acute | Stable | Operating-margin gap against peers — -47.8 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Allergy Therapeutics